Similar Search Results

Gafni, Amiram - In: PharmacoEconomics 14 (1998) 5, pp. 465-470

Despite renewed enthusiasm for the use of willingness to pay (WTP) in healthcare applications, there are still a lot of objections, resentment and scepticism regarding the desirability and feasibility of this technique. Objections can be classified into different categories: e.g. theoretical,...

Persistent link: https://www.econbiz.de/10005449276

Cost-Benefit Analysis of Haemophilus influenzae Type b Vaccination in Children in Spain

Jimenez, F. Javier; Guallar-Castillon, Pilar; Terres, … - In: PharmacoEconomics 15 (1999) 1, pp. 75-83

Objective: Invasive disease caused by Haemophilus influenzae type b (Hib), including meningitis, pneumonia, sepsis and epiglottitis, is associated with high mortality and serious neurological sequelae in children under 5 years of age. The availability of an efficacious vaccine suggests the need...

Persistent link: https://www.econbiz.de/10005449321

Economic Impact of Providing Workplace Influenza Vaccination: A Model and Case Study Application at a Brazilian Pharma-Chemical Company

Burckel, Emmanuel; Ashraf, Talat; Galvao de Sousa … - In: PharmacoEconomics 16 (1999) 5, pp. 563-576

Objective: To develop and apply a model to assess the economic value of a workplace influenza programme from the perspective of the employer. Design: The model calculated the avoided costs of influenza, including treatment costs, lost productivity, lost worker added value and the cost of...

Persistent link: https://www.econbiz.de/10005404933

Recent Advances in the Methods of Cost-Benefit Analysis in Healthcare: Matching the Art to the Science

McIntosh, Emma; Donaldson, Cam; Ryan, Mandy - In: PharmacoEconomics 15 (1999) 4, pp. 357-367

This paper outlines recent advances in the methods of cost-benefit analysis (CBA). Economic evaluations in healthcare can be criticised for, amongst other things, the inappropriate use of incremental cost-effectiveness ratios and the reporting of benefits in terms of cost savings, such as...

Persistent link: https://www.econbiz.de/10005590453

Acamprosate: Pharmacoeconomic Implications of Therapy

Foster, Rachel H.; McClellan, Karen J. - In: PharmacoEconomics 16 (1999) 6, pp. 743-755

_ Acamprosate is thought to reduce the craving for alcohol. The drug helps to maintain abstinence in alcohol-dependent patients who have successfully undergone detoxification. Abstinence rates during 3 to 12 months' treatment with acamprosate were approximately double those with placebo in most...

Persistent link: https://www.econbiz.de/10005590558

Early Recognition and Intervention: The Key to Success in the Treatment of Schizophrenia?

Johannessen, Jan Olav - In: Disease Management and Health Outcomes 9 (2001) 6, pp. 317-327

Schizophrenia is possibly the single most costly disorder in psychiatric or somatic medicine, despite a relatively low … be due to an apparent delay in providing treatment early in the course of the illness. Schizophrenia can be regarded as a … treatment for schizophrenia may improve the course of the disorder. Projects aimed at intervening in the prodromal phase of the …

Persistent link: https://www.econbiz.de/10005448910

Interventions for Families of Individuals with Schizophrenia: Maximising Outcomes for their Relatives

Solomon, Phyllis - In: Disease Management and Health Outcomes 8 (2000) 4, pp. 211-221

with schizophrenia. This article delineates the various family interventions and the empirical base of these interventions … families of adults with schizophrenia. Providers and organisations need to understand the needs of families, become …

Persistent link: https://www.econbiz.de/10005448942

Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia: Results From a Randomised Clinical Trial

Hamilton, Susan H.; Revicki, Dennis A.; Edgell, Eric T.; … - In: PharmacoEconomics 15 (1999) 5, pp. 469-480

olanzapine to those of haloperidol for the treatment of schizophrenia. Design and setting: Clinical, quality-of-life and resource … utilisation data were prospectively collected for US-residing patients with schizophrenia who were participating in a multicentre … standardised prices (1995 values) to the resource utilisation data. Patients and participants: 817 patients with schizophrenia who …

Persistent link: https://www.econbiz.de/10005449144

Hospital Length of Stay for Schizophrenia: Is Primary Payer an Influencing Factor?

Sclar, David A.; Robison, Linda M.; Skaer, Tracy L.; … - In: Disease Management and Health Outcomes 5 (1999) 6, pp. 339-347

schizophrenia and requiring a hospitalisation in the calendar year 1988 or 1992, by primary payer type (Medicare; Medicaid; or …-9-CM) diagnostic code of 295.00 to 295.95, indicating schizophrenia as the primary diagnosis; were hospitalised between … factors, the mean hospital length of stay for schizophrenia decreased by over 1 day (from 10.1 to 9.0; p <= 0.0001) between …

Persistent link: https://www.econbiz.de/10005590212

Assessing Health Utilities in Schizophrenia: A Feasibility Study

Voruganti, Lakshmi N.; Awad, A. George; Oyewumi, L. Kola; … - In: PharmacoEconomics 17 (2000) 3, pp. 273-286

individuals affected by a chronic illness such as schizophrenia. Traditional techniques of utility measurement involve 2 steps: (i … accurate health state descriptions and their utilities from symptomatically stable patients with schizophrenia. Methods: The … with schizophrenia and a control group of 32 treated and recovered patients with major depression. Patients were asked to …

Persistent link: https://www.econbiz.de/10005590351